Category Archives: R&D

Patient commentary: the current model has failed

Source: BMJ The cost of cancer drugs is skyrocketing: prices of cancer drugs increased by 10% every year between 1995 and 2013.1 More and more we’re seeing cancer drugs being priced off the NHS—as is the case with secondary breast cancer … Continue reading

Posted in Cancer, Drug prices, R&D, Uncategorized | Leave a comment

Pharmaceutical Pricing Hostages

By Ellen t’ Hoen, Medicines Law & Policy Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring announced it will no longer provide Respreeza (human alpha1-proteinase inhibitor), … Continue reading

Posted in R&D, Uncategorized | Leave a comment

UACT ASKS CEOS FOR TRANSPARENCY ON CAR T TREATMENTS

Today, UACT submitted letters to the CEOs of three major pharmaceutical companies currently developing chimeric antigen receptor T-cell (CAR T) technologies.  UACT asked the leaders of Novartis, Gilead Sciences, and Juno Therapeutics to address questions regarding research and development (R&D) … Continue reading

Posted in Cancer, Drug prices, Gene Therapy, Patent, R&D, Uncategorized | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

South African IP policy draft released seeking comments from public

International Trade and Economic Development division of South African Government has released the  Draft Intellectual Property Policy of the Republic of south Africa Phase 2017 and it is now publicly available for comments.  Access the draft policy here: http://www.dti.gov.za/gazzettes/IP_Policy.pdf   

Posted in IPR, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- James Love, Knowledge Ecology International

These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading

Posted in Delinkage, FTA, IPR, Patent, R&D, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Escaping Big Pharma’s Pricing With Patent-Free Drugs

Source: New York Times How’s this for a great deal? The United States government funded research and development of a new vaccine against Zika. But the Army, which paid a French pharmaceutical manufacturer for its development, is planning to grant exclusive … Continue reading

Posted in Patent, R&D, Uncategorized | Leave a comment